Answering important clinical questions — such as whether genetic diversity is a risk factor for aggressive tumor development or how it relates to treatment resistance — requires analyzing samples from many
patients with different types of cancer.
The NYGC and its founding member institutions are conducting additional studies involving Watson to help accelerate the discovery of potentially actionable sequence variants in various types of cancer, including an ongoing study that involves DNA and RNA from a larger cohort of glioblastoma patients, and a study of 200
patients with different types of cancer.
Wistar discoveries have led to the development of vaccines for rabies, rubella, and rotavirus, the identification of genes
associated with different types of cancer, the development of monoclonal antibodies, and other significant research technologies and tools.